BigWorm129 You are correct. I have done consulting for both Genzyme and Biogen, two of the very successful biotechs that made it as Major Pharmas. Both Genzyme and Biogen as young biotechs had the right blend of successful IP researchers combined with those savvy business individuals. This has been sadly lacking in $OCAT before the Dr. Paul Wotton leadership. I have renewed hope now that Dr. Wotton has taken control and $OCAT is being shaped as a Major Pharma would be.
Market Data 
Markets 
AI
